Shingles vaccines may reduce dementia risk, two large new studies ... - CNN
Jul 30, 2024 · CNN — Two new studies suggest that getting a vaccine to protect against a painful case of shingles may be beneficial for memory, too. An estimated 98% of US adults have had chickenpox and are at...
Shingles vaccine may lower dementia risk - Parsemus Foundation
2 days ago · The recombinant zoster vaccine known as SHINGRIX may also lower the risk of developing dementia, according to a new study. The vaccine prevents shingles, a painful viral infection, and is typically recommended for those 50 and older. Researchers in the U.K. published a study in Nature Medicine on July 25 that showed that among people diagnosed ...
Large study of shingles vaccine finds strong effectiveness over 4 …
Jan 8, 2024 · In 2021, the CDC Advisory Committee on Immunization Practices voted to recommend Shingrix to immunocompromised people ages 19 years or older. Previously, older adults in the U.S. were given a live shingles vaccine (Zostavax), which waned significantly in the years following vaccination.
Pfizer and BioNTech Initiate Phase 1/2 Study of First mRNA-based ...
Feb 10, 2023 · NEW YORK and MAINZ, GERMANY, FEBRUARY 10, 2023 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the start of a Phase 1/2 trial exploring the safety, tolerability, and immunogenicity of the companies’ mRNA vaccine candidates against shingles (also known as herpes zoster, or HZ), a debilitating disease caused by the ...
Two-dose shingles vaccine is still highly effective after four years
Apr 1, 2024 · The CDC recommends adults ages 50 and older get two doses of the recombinant zoster vaccine (Shingrix), with the doses separated by two to six months, to prevent shingles. But how long can it offer protection?
New long-term data show SHINGRIX continues to provide high
Apr 17, 2024 · GSK plc (LSE/NYSE: GSK) today announced positive data from the ZOSTER-049 long-term follow-up phase III trial which followed participants for up to approximately 11 years following initial vaccination with SHINGRIX (Recombinant Zoster Vaccine or RZV).
New shingles vaccine could reduce risk of dementia
Jul 25, 2024 · The new recombinant shingles vaccine ‘Shingrix’ is associated with a reduced risk of dementia compared to an earlier shingles vaccine, according to a major new study published in Nature Medicine. It is also more protective than vaccines against other infections.
New study examines long term effectiveness of live shingles vaccine
Nov 8, 2023 · Live zoster vaccine was the first vaccine against shingles; over 50 million people have received it worldwide. It is not currently recommended for people with a weakened immune system...
Could the Shingles Vaccine Protect Against Dementia?
Oct 18, 2024 · If shingles vaccines protect against dementia by preventing small, recurring reactivations of herpes zoster, then the more efficacious recombinant vaccine would be expected to be superior to the live virus vaccine, Geldsetzer explained.
Shingles Vaccine Recommendations | Shingles (Herpes Zoster)
Oct 22, 2024 · CDC recommends Shingrix (recombinant zoster vaccine or RZV) for the prevention of herpes zoster (shingles) and related complications. This page summarizes CDC's current shingles vaccine recommendations.